Publications by authors named "Rami Komrokji"

100Publications

What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia.

J Natl Compr Canc Netw 2020 09;18(9):1279-1284

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2020.7595DOI Listing
September 2020

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Cancers (Basel) 2020 Aug 14;12(8). Epub 2020 Aug 14.

Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12082278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464183PMC
August 2020

Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.

Clin Lymphoma Myeloma Leuk 2020 Jul 16. Epub 2020 Jul 16.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.07.006DOI Listing
July 2020

Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL).

Leukemia 2020 Jun 21. Epub 2020 Jun 21.

Formerly Department of Malignant Hematology, H. Lee Moffitt Cancer center, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0928-4DOI Listing
June 2020

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.

Clin Lymphoma Myeloma Leuk 2020 Sep 20;20(9):e597-e605. Epub 2020 Mar 20.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.03.005DOI Listing
September 2020

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.

Clin Lymphoma Myeloma Leuk 2020 06 10;20(6):400-406.e2. Epub 2020 Jan 10.

Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.12.023DOI Listing
June 2020

Defining Acute Myeloid Leukemia Ontogeny in Older Patients.

Clin Lymphoma Myeloma Leuk 2020 05 9;20(5):312-315. Epub 2019 Nov 9.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.11.007DOI Listing
May 2020

Luspatercept in Myelodysplastic Syndromes: Who and When?

Authors:
Rami S Komrokji

Hematol Oncol Clin North Am 2020 Apr 21;34(2):393-400. Epub 2020 Jan 21.

Malignant Hematology Department, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2019.10.004DOI Listing
April 2020

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.

Clin Lymphoma Myeloma Leuk 2020 05 14;20(5):324-328. Epub 2020 Jan 14.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.01.003DOI Listing
May 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

N Engl J Med 2020 01;382(2):140-151

From Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d'Azur, Département d'Hématologie Clinique, CHU Nice, Nice (T.C.) - all in France; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig (U.P.), Klinik für Hämatologie, Onkologie, and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf (U.G.), and Klinik und Poliklinik für Innere Medizin III, Technische Universität München, Munich (K.S.G.) - all in Germany; the Department of Haemato-Oncology, King's College London, London (G.J.M.), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford (P.V.), and the Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds (D.B.) - all in the United Kingdom; the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.G.-M.); Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (R.B.); MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence (V.S.), the Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna (C.F.), the University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia (M.C.), the Hematology Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (F.S., V.G.), and Dipartimento Biomedicina e Prevenzione, University of Rome Tor Vergata, Rome (M.-T.V.) - all in Italy; the Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca (M.D.-C.), Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville (J.F.F.), and the Department of Hematology, Hospital Universitario Cruces, Vizcaya (B.A.) - all in Spain; the Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey (O.I.); the Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland (M.A.S.); the Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges (D.S.), and Universitair Ziekenhuis Gent, Ghent (D.M.) - both in Belgium; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (A.E.D.); the Division of Hematology-Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (J.G.J.), and Albert Einstein College of Medicine (A.V.) - both in New York; the Department of Hematology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands (E.V.); Stanford University Cancer Center, Stanford, CA (P.L.G.); the Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm (E.H.-L.); the Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT (A.M.Z.); Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville (M.R.S.); Celgene, Summit, NJ (A.L., J.Z., A.R., D.R.D.); Celgene International, Boudry, Switzerland (A.B.); Acceleron Pharma, Cambridge, MA (P.G.L., M.L.S.); and Moffitt Cancer Center, Tampa, FL (R.S.K., A.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908892DOI Listing
January 2020

Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.

J Clin Pathol 2020 Apr 26;73(4):209-212. Epub 2019 Nov 26.

Hematopathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-206132DOI Listing
April 2020

Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study.

J Vasc Interv Radiol 2020 Apr 27;31(4):584-591. Epub 2019 Aug 27.

Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2019.05.031DOI Listing
April 2020

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Am J Hematol 2019 12 10;94(12):E314-E317. Epub 2019 Sep 10.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25625DOI Listing
December 2019

Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.

Authors:
Rami S Komrokji

Curr Hematol Malig Rep 2019 08;14(4):346-351

Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00517-9DOI Listing
August 2019

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Leuk Res 2019 06 30;81:56-61. Epub 2019 Mar 30.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.008DOI Listing
June 2019

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).

Clin Lymphoma Myeloma Leuk 2019 01 23;19(1):1-8. Epub 2018 Nov 23.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493410PMC
January 2019

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Cancer 2018 12 5;124(24):4601-4609. Epub 2018 Oct 5.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31769
Publisher Site
http://dx.doi.org/10.1002/cncr.31769DOI Listing
December 2018

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Clin Lymphoma Myeloma Leuk 2018 08 26;18(8):528-532. Epub 2018 May 26.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.05.016DOI Listing
August 2018

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.

Expert Rev Hematol 2018 07 19;11(7):577-586. Epub 2018 Jun 19.

b Malignant Hematology Department , Moffitt Cancer Center , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1486188DOI Listing
July 2018

Azacitidine Use for Myeloid Neoplasms.

Clin Lymphoma Myeloma Leuk 2018 04 8;18(4):e147-e155. Epub 2018 Feb 8.

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.02.005DOI Listing
April 2018

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

Br J Haematol 2019 02 23;184(3):450-455. Epub 2018 Jan 23.

Departments of Hematopathology and Clinical Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15099DOI Listing
February 2019

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Ann Hematol 2018 Mar 30;97(3):435-441. Epub 2017 Nov 30.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3194-4DOI Listing
March 2018

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Blood Cancer J 2017 11 27;7(12):633. Epub 2017 Nov 27.

Hematopathology and Laboratory Medicine Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 36612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-017-0004-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802523PMC
November 2017

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Ann Hematol 2018 Feb 22;97(2):247-254. Epub 2017 Nov 22.

Department of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-017-3186-4
Publisher Site
http://dx.doi.org/10.1007/s00277-017-3186-4DOI Listing
February 2018

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2017 Dec 19;17(12):902-907. Epub 2017 Sep 19.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.09.007DOI Listing
December 2017

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Clin Lymphoma Myeloma Leuk 2017 Dec 5;17(12):e45-e53. Epub 2017 Aug 5.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.08.002DOI Listing
December 2017

Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.

Crit Rev Oncol Hematol 2017 Sep 12;117:57-66. Epub 2017 Jul 12.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.07.002DOI Listing
September 2017

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Cancer 2017 Oct 31;123(19):3662-3672. Epub 2017 Jul 31.

Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30903DOI Listing
October 2017

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Clin Lymphoma Myeloma Leuk 2017 08 12;17(8):479-487. Epub 2017 May 12.

Division of Cancer Medicine, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.05.015DOI Listing
August 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

J Clin Oncol 2017 May 28;35(14):1591-1597. Epub 2017 Mar 28.

Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Université Grenoble Alpes, Grenoble; Jean-François Hamel and Sylvain Thépot, CHU d'Angers; Sylvain Thépot, Université d'Angers, Institut National de la Santé et de la Recherche Médicale, Unité 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Université Paris X; François Dreyfus, CHU Cochin, AP-HP, Université Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnès Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stéphane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon; Christian Rose, Université Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de León, León; Marisa Calabuig, Hospital Clínico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Università degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Università Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Düsseldorf, Düsseldorf; Katharina Götze and Catharina Müller-Thomas, Universität München, München, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3271DOI Listing
May 2017

Use of eltrombopag for treatment of myelodysplastic syndromes.

Authors:
Rami S Komrokji

Lancet Haematol 2017 03;4(3):e99-e100

H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(17)30017-0DOI Listing
March 2017

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.

Clin Lymphoma Myeloma Leuk 2017 04 10;17(4):211-214. Epub 2017 Jan 10.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.10.003DOI Listing
April 2017

Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Clin Lymphoma Myeloma Leuk 2017 01 16;17(1):7-13. Epub 2016 Sep 16.

Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.09.005DOI Listing
January 2017

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

J Exp Pharmacol 2016 16;8:11-9. Epub 2016 Aug 16.

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JEP.S110702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993559PMC
August 2016

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Onco Targets Ther 2016 10;9:4937-57. Epub 2016 Aug 10.

Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S102504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986686PMC
August 2016

Ruxolitinib dose management as a key to long-term treatment success.

Int J Hematol 2016 Oct 27;104(4):420-9. Epub 2016 Aug 27.

Division of Cancer Medicine, Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-016-2084-1DOI Listing
October 2016